Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Department of Nuclear Medicine, Changhai Hospital of Shanghai, Shanghai, China.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Mar;14(2):e1749. doi: 10.1002/wnan.1749. Epub 2021 Aug 17.
Transarterial chemoembolization (TACE) is a recommended treatment for patients suffering from intermediate and advanced hepatocellular carcinoma (HCC). As compared to the conventional TACE, drug-eluting bead TACE demonstrates several advantages in terms of survival, treatment response, and adverse effects. The selection of embolic agents is critical to the success of TACE. Many studies have been performed on the modification of the structure, size, homogeneity, biocompatibility, and biodegradability of embolic agents. Continuing efforts are focused on efficient loading of versatile chemotherapeutics, controlled sizes for sufficient occlusion, real-time detection intra- and post-procedure, and multimodality imaging-guided precise treatment. Here, we summarize recent advances and applications of microspheres and nanoparticles in TACE for HCC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
经动脉化疗栓塞术（TACE）是治疗中晚期肝细胞癌（HCC）的推荐疗法。与传统 TACE 相比，载药微球 TACE 在生存、治疗反应和不良反应方面具有明显优势。栓塞剂的选择对 TACE 的成功至关重要。许多研究致力于栓塞剂的结构、大小、均匀性、生物相容性和生物降解性的改良。目前的研究重点是高效装载各种化疗药物、实现充分闭塞所需的载药微球和纳米粒的精准可控大小、实时术中及术后检测以及多模态影像引导的精准治疗。本文综述了载药微球和纳米粒在 HCC 中的 TACE 中的最新进展和应用。本文属于以下类别：治疗方法和药物发现 > 用于肿瘤疾病的纳米医学。
